| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Wistar Institute [K. S., G. L., M. H.]; Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center [M. R. G., M. S. B., P. V., B. L. W.]; and Anatomic Pathology, Hospital of the University of Pennsylvania [P. v. B., D. E. E.], Philadelphia, Pennsylvania 19104
Dysregulated activation of Ras or its downstream effectors such as mitogen-activated protein kinase kinase and ERK has been shown to play a critical role in tumorigenesis of many cancer types. However, in melanoma, activating mutations in Ras are rarely observed and are limited to N-Ras in UV-exposed cells. In this study, we identify constitutively activated ERK in almost all melanoma cell lines and in tumor tissues tested, which is in contrast to normal melanocytes and several early stage radial growth phase melanoma lines where ERK can be activated by serum or growth factors. Constitutive activation of ERK is preceded by phosphorylation of mitogen-activated protein kinase kinase and c-RAF. In all of the melanoma cell lines tested, Ras is constitutively activated without underlying mutations. On the contrary, activating mutations in the kinase domain of BRAF are present in the majority of the cell lines tested. Furthermore, ERK activation can be partially inhibited from the cell surface using inhibitors of fibroblast growth factor and hepatocyte growth factor but not interleukin 8 signaling pathways. These data suggest that melanoma growth, invasion, and metastasis are attributable to constitutively activated ERK apparently mediated by excessive growth factors through autocrine mechanisms and BRAF kinase activation.
This article has been cited by other articles:
![]() |
M. Muller, M. Obeyesekere, G. B. Mills, and P. T. Ram Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R FASEB J, May 1, 2008; 22(5): 1393 - 1403. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Maat, S. H. W. Beiboer, M. J. Jager, G. P. M. Luyten, N. A. Gruis, and P. A. van der Velden Epigenetic Regulation Identifies RASEF as a Tumor-Suppressor Gene in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1291 - 1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sun, F. Wu, F. Sun, and P. Huang Adenosine Promotes IL-6 Release in Airway Epithelia J. Immunol., March 15, 2008; 180(6): 4173 - 4181. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Maat, E. Kilic, G. P. M. Luyten, A. de Klein, M. J. Jager, N. A. Gruis, and P. A. Van der Velden Pyrophosphorolysis Detects B-RAF Mutations in Primary Uveal Melanoma Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 23 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Haass, K. Sproesser, T. K. Nguyen, R. Contractor, C. A. Medina, K. L. Nathanson, M. Herlyn, and K. S.M. Smalley The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel Clin. Cancer Res., January 1, 2008; 14(1): 230 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F. Gajewski, E. A. Grimm, B. J. Nickoloff, and A. T. Weeraratna New Potential Therapeutic Targets in Melanoma ASCO Educational Book, January 1, 2008; 2008(1): 404 - 407. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Liao, S.-M. Hsu, and P.-H. Huang ARMS Depletion Facilitates UV Irradiation Induced Apoptotic Cell Death in Melanoma Cancer Res., December 15, 2007; 67(24): 11547 - 11556. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nakamura, B. Han, T. Nishishita, Y. Bai, and K. Kakudo Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers J. Mol. Endocrinol., December 1, 2007; 39(6): 375 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Blackburn, C. H. Rhodes, C. I. Coon, and C. E. Brinckerhoff RNA Interference Inhibition of Matrix Metalloproteinase-1 Prevents Melanoma Metastasis by Reducing Tumor Collagenase Activity and Angiogenesis Cancer Res., November 15, 2007; 67(22): 10849 - 10858. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. F. Wang, C. C. Jiang, K. A. Kiejda, S. Gillespie, X. D. Zhang, and P. Hersey Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1 Clin. Cancer Res., August 15, 2007; 13(16): 4934 - 4942. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-N. Zhu, H.-J. He, S. Kole, T. D'Souza, R. Agarwal, P. J. Morin, and M. Bernier Filamin A-mediated Down-regulation of the Exchange Factor Ras-GRF1 Correlates with Decreased Matrix Metalloproteinase-9 Expression in Human Melanoma Cells J. Biol. Chem., May 18, 2007; 282(20): 14816 - 14826. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yancovitz, J. Yoon, M. Mikhail, W. Gai, R. L. Shapiro, R. S. Berman, A. C. Pavlick, P. B. Chapman, I. Osman, and D. Polsky Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma J. Mol. Diagn., April 1, 2007; 9(2): 178 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Kumar, H. Yu, R. Edwards, L. Chen, S. Kazianis, P. Brafford, G. Acs, M. Herlyn, and X. Xu Mutant V600E BRAF Increases Hypoxia Inducible Factor-1{alpha} Expression in Melanoma Cancer Res., April 1, 2007; 67(7): 3177 - 3184. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shinozaki, S. J. O'Day, M. Kitago, F. Amersi, C. Kuo, J. Kim, H.-J. Wang, and D. S.B. Hoon Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy Clin. Cancer Res., April 1, 2007; 13(7): 2068 - 2074. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Namkoong, S.-S. Shin, H. J. Lee, Y. E. Marin, B. A. Wall, J. S. Goydos, and S. Chen Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma Cancer Res., March 1, 2007; 67(5): 2298 - 2305. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Mitsiades, J. Negri, C. McMullan, D. W. McMillin, E. Sozopoulos, G. Fanourakis, G. Voutsinas, S. Tseleni-Balafouta, V. Poulaki, D. Batt, et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications Mol. Cancer Ther., March 1, 2007; 6(3): 1070 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Slupsky, A. S. Kamiguti, R. J. Harris, J. C. Cawley, and M. Zuzel Central Role of Protein Kinase C{epsilon} in Constitutive Activation of ERK1/2 and Rac1 in the Malignant Cells of Hairy Cell Leukemia Am. J. Pathol., February 1, 2007; 170(2): 745 - 754. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Jane, D. R. Premkumar, and I. F. Pollack Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1070 - 1080. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kono, I. S. Dunn, P. J. Durda, D. Butera, L. B. Rose, T. J. Haggerty, E. M. Benson, and J. T. Kurnick Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression Mol. Cancer Res., October 1, 2006; 4(10): 779 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Spofford, E. V. Abel, K. Boisvert-Adamo, and A. E. Aplin Cyclin D3 Expression in Melanoma Cells Is Regulated by Adhesion-dependent Phosphatidylinositol 3-Kinase Signaling and Contributes to G1-S Progression J. Biol. Chem., September 1, 2006; 281(35): 25644 - 25651. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. James, T. Dumeni, M. S. Stark, D. L. Duffy, G. W. Montgomery, N. G. Martin, and N. K. Hayward Rapid Screening of 4000 Individuals for Germ-line Variations in the BRAF Gene Clin. Chem., September 1, 2006; 52(9): 1675 - 1678. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sharma, M. A. Tran, S. Liang, A. K. Sharma, S. Amin, C. D. Smith, C. Dong, and G. P. Robertson Targeting Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases Cancer Res., August 15, 2006; 66(16): 8200 - 8209. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Kokkinakis, A. G. Brickner, J. M. Kirkwood, X. Liu, J. E. Goldwasser, A. Kastrama, C. Sander, D. Bocangel, and S. Chada Mitotic Arrest, Apoptosis, and Sensitization to Chemotherapy of Melanomas by Methionine Deprivation Stress Mol. Cancer Res., August 1, 2006; 4(8): 575 - 589. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tormo, A. Ferrer, E. Gaffal, J. Wenzel, E. Basner-Tschakarjan, J. Steitz, L. C. Heukamp, I. Gutgemann, R. Buettner, M. Malumbres, et al. Rapid Growth of Invasive Metastatic Melanoma in Carcinogen-Treated Hepatocyte Growth Factor/Scatter Factor-Transgenic Mice Carrying an Oncogenic CDK4 Mutation Am. J. Pathol., August 1, 2006; 169(2): 665 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sumimoto, F. Imabayashi, T. Iwata, and Y. Kawakami The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells J. Exp. Med., July 10, 2006; 203(7): 1651 - 1656. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tormo, A. Ferrer, P. Bosch, E. Gaffal, E. Basner-Tschakarjan, J. Wenzel, and T. Tuting Therapeutic Efficacy of Antigen-Specific Vaccination and Toll-Like Receptor Stimulation against Established Transplanted and Autochthonous Melanoma in Mice. Cancer Res., May 15, 2006; 66(10): 5427 - 5435. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Calipel, F. Mouriaux, A.-L. Glotin, F. Malecaze, A.-M. Faussat, and F. Mascarelli Extracellular Signal-regulated Kinase-dependent Proliferation Is Mediated through the Protein Kinase A/B-Raf Pathway in Human Uveal Melanoma Cells J. Biol. Chem., April 7, 2006; 281(14): 9238 - 9250. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Flaherty Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res., April 1, 2006; 12(7): 2366s - 2370s. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Panka, M. B. Atkins, and J. W. Mier Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin. Cancer Res., April 1, 2006; 12(7): 2371s - 2375s. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Sosman and I. Puzanov Molecular targets in melanoma from angiogenesis to apoptosis. Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Panka, W. Wang, M. B. Atkins, and J. W. Mier The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells Cancer Res., February 1, 2006; 66(3): 1611 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Grbovic, A. D. Basso, A. Sawai, Q. Ye, P. Friedlander, D. Solit, and N. Rosen V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors PNAS, January 3, 2006; 103(1): 57 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Emuss, M. Garnett, C. Mason, The Cancer Genome Project, and R. Marais Mutations of C-RAF Are Rare in Human Cancer because C-RAF Has a Low Basal Kinase Activity Compared with B-RAF Cancer Res., November 1, 2005; 65(21): 9719 - 9726. [Abstract] [Full Text] [PDF] |
||||
![]() |
L Zhuang, C S Lee, R A Scolyer, S W McCarthy, A A Palmer, X D Zhang, J F Thompson, L P Bron, and P Hersey Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma J. Clin. Pathol., November 1, 2005; 58(11): 1163 - 1169. [Abstract] [Full Text] [PDF] |
||||
![]() |
I.-M. Shih and R. J. Kurman Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges Clin. Cancer Res., October 15, 2005; 11(20): 7273 - 7279. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kobel, G. Pohl, W. D. Schmitt, S. Hauptmann, T.-L. Wang, and I.-M. Shih Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor Am. J. Pathol., September 1, 2005; 167(3): 879 - 885. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bloethner, B. Chen, K. Hemminki, J. Muller-Berghaus, S. Ugurel, D. Schadendorf, and R. Kumar Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines Carcinogenesis, July 1, 2005; 26(7): 1224 - 1232. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sharma, N. R. Trivedi, M. A. Zimmerman, D. A. Tuveson, C. D. Smith, and G. P. Robertson Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors Cancer Res., March 15, 2005; 65(6): 2412 - 2421. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Bao and S. Stromblad Integrin {alpha}v-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen J. Cell Biol., November 22, 2004; 167(4): 745 - 756. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Hazarika, M. F. McCarty, V. G. Prieto, S. George, D. Babu, D. Koul, M. Bar-Eli, and M. Duvic Up-regulation of Flotillin-2 Is Associated with Melanoma Progression and Modulates Expression of the Thrombin Receptor Protease Activated Receptor 1 Cancer Res., October 15, 2004; 64(20): 7361 - 7369. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-L. Ho, R. J. Kurman, R. Dehari, T.-L. Wang, and I.-M. Shih Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors Cancer Res., October 1, 2004; 64(19): 6915 - 6918. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Steinmetz, H. A. Wagoner, P. Zeng, J. R. Hammond, T. S. Hannon, J. L. Meyers, and O. H. Pescovitz Mechanisms Regulating the Constitutive Activation of the Extracellular Signal-Regulated Kinase (ERK) Signaling Pathway in Ovarian Cancer and the Effect of Ribonucleic Acid Interference for ERK1/2 on Cancer Cell Proliferation Mol. Endocrinol., October 1, 2004; 18(10): 2570 - 2582. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamaguchi, D. P. Wallace, B. S. Magenheimer, S. J. Hempson, J. J. Grantham, and J. P. Calvet Calcium Restriction Allows cAMP Activation of the B-Raf/ERK Pathway, Switching Cells to a cAMP-dependent Growth-stimulated Phenotype J. Biol. Chem., September 24, 2004; 279(39): 40419 - 40430. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tsavachidou, M. L. Coleman, G. Athanasiadis, S. Li, J. D. Licht, M. F. Olson, and B. L. Weber SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant Cancer Res., August 15, 2004; 64(16): 5556 - 5559. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Huntington, J. M. Shields, C. J. Der, C. A. Wyatt, U. Benbow, C. L. Slingluff Jr., and C. E. Brinckerhoff Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells: ROLE OF BRAF MUTATION AND FIBROBLAST GROWTH FACTOR SIGNALING J. Biol. Chem., August 6, 2004; 279(32): 33168 - 33176. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Schuierer, F. Bataille, S. Hagan, W. Kolch, and A.-K. Bosserhoff Reduction in Raf Kinase Inhibitor Protein Expression Is Associated with Increased Ras-Extracellular Signal-Regulated Kinase Signaling in Melanoma Cell Lines Cancer Res., August 1, 2004; 64(15): 5186 - 5192. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lefevre, A.-L. Glotin, A. Calipel, F. Mouriaux, T. Tran, Z. Kherrouche, C.-A. Maurage, C. Auclair, and F. Mascarelli Roles of Stem Cell Factor/c-Kit and Effects of Glivec(R)/STI571 in Human Uveal Melanoma Cell Tumorigenesis J. Biol. Chem., July 23, 2004; 279(30): 31769 - 31779. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Tague, V. Muralidharan, and C. D'Souza-Schorey ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway PNAS, June 29, 2004; 101(26): 9671 - 9676. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yang, M. A. Price, C. L. Neudauer, C. Wilson, S. Ferrone, H. Xia, J. Iida, M. A. Simpson, and J. B. McCarthy Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms J. Cell Biol., June 21, 2004; 165(6): 881 - 891. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Lev, A. Onn, V. O. Melinkova, C. Miller, V. Stone, M. Ruiz, E. C. McGary, H. N. Ananthaswamy, J. E. Price, and M. Bar-Eli Exposure of Melanoma Cells to Dacarbazine Results in Enhanced Tumor Growth and Metastasis In Vivo J. Clin. Oncol., June 1, 2004; 22(11): 2092 - 2100. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wellbrock, L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, D. Niculescu-Duvaz, C. J. Springer, and R. Marais V599EB-RAF is an Oncogene in Melanocytes Cancer Res., April 1, 2004; 64(7): 2338 - 2342. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bedogni, M. S. O'Neill, S. M. Welford, D. M. Bouley, A. J. Giaccia, N. C. Denko, and M. B. Powell Topical Treatment with Inhibitors of the Phosphatidylinositol 3'-Kinase/Akt and Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathways Reduces Melanoma Development in Severe Combined Immunodeficient Mice Cancer Res., April 1, 2004; 64(7): 2552 - 2560. [Abstract] [Full Text] [PDF] |
||||
![]() |
R H Edwards, M R Ward, H Wu, C A Medina, M S Brose, P Volpe, S Nussen-Lee, H M Haupt, A M Martin, M Herlyn, et al. Absence of BRAF mutations in UV-protected mucosal melanomas J. Med. Genet., April 1, 2004; 41(4): 270 - 272. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Perlis and M. Herlyn Recent Advances in Melanoma Biology Oncologist, April 1, 2004; 9(2): 182 - 187. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shinozaki, A. Fujimoto, D. L. Morton, and D. S. B. Hoon Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas Clin. Cancer Res., March 1, 2004; 10(5): 1753 - 1757. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bagnato, L. Rosano, F. Spinella, V. Di Castro, R. Tecce, and P. G. Natali Endothelin B Receptor Blockade Inhibits Dynamics of Cell Interactions and Communications in Melanoma Cell Progression Cancer Res., February 15, 2004; 64(4): 1436 - 1443. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Eisenmann, M. W. VanBrocklin, N. A. Staffend, S. M. Kitchen, and H.-M. Koo Mitogen-Activated Protein Kinase Pathway-Dependent Tumor-Specific Survival Signaling in Melanoma Cells through Inactivation of the Proapoptotic Protein Bad Cancer Res., December 1, 2003; 63(23): 8330 - 8337. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Jorgensen, R. Holm, G. M. Maelandsmo, and V. A. Florenes Expression of Activated Extracellular Signal-Regulated Kinases 1/2 in Malignant Melanomas: Relationship with Clinical Outcome Clin. Cancer Res., November 1, 2003; 9(14): 5325 - 5331. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Rimoldi, S. Salvi, D. Lienard, F. J. Lejeune, D. Speiser, L. Zografos, and J.-C. Cerottini Lack of BRAF Mutations in Uveal Melanoma Cancer Res., September 15, 2003; 63(18): 5712 - 5715. [Abstract] [Full Text] [PDF] |
||||
![]() |